Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT
Phase 4
Not yet recruiting
- Conditions
- To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Target Recruit Count
- 31
- Registration Number
- NCT05914701
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1
Not yet recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Biological: YTS104 Cells injection
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Target Recruit Count
- 8
- Registration Number
- NCT05913804
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation
Not Applicable
Recruiting
- Conditions
- COVID-19Hematopoietic Stem Cell Transplantation
- Interventions
- Biological: COVID Convalescent Plasma
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Target Recruit Count
- 72
- Registration Number
- NCT05904067
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, None Selected, China
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Phase 4
Recruiting
- Conditions
- Hemophilia A With Inhibitor
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 50
- Registration Number
- NCT05888870
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Phase 2
Recruiting
- Conditions
- Polycythemia Vera
- Interventions
- Drug: Pegylated interferon α-2b
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 94
- Registration Number
- NCT05870475
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Phase 2
Recruiting
- Conditions
- Plasma Cell Leukemia
- Interventions
- Biological: anti-BCMA CAR-T
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 20
- Registration Number
- NCT05870917
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Biological: anti-BCMA CAR-TDrug: VRd
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-01-26
- Target Recruit Count
- 40
- Registration Number
- NCT05860036
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
Not Applicable
Active, not recruiting
- Conditions
- Transfusion-dependent Beta-Thalassemia
- Interventions
- Genetic: KL003 cell injection Drug Product
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2025-03-14
- Target Recruit Count
- 3
- Registration Number
- NCT05860595
- Locations
- 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
Phase 4
Recruiting
- Conditions
- Acquired Hemophilia
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2025-02-21
- Target Recruit Count
- 10
- Registration Number
- NCT05849740
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, China
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
Phase 2
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Biological: anti-BCMA CAR-TDrug: VRD-based Regimen
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 20
- Registration Number
- NCT05850286
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath